We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Enzyme Immunoassays Employed to Diagnose Neurocysticercosis

By LabMedica International staff writers
Posted on 18 Jan 2012
Enzyme immunoassays have been tested for detecting antibodies against the pork tapeworm in human serum and for the diagnosis of neurocysticercosis. More...


All of the five commercial tests compared were enzyme immunoassays for the qualitative determination of the immunoglobulin G (IgG) class of antibodies against Taenia solium, the causative agent of neurocysticercosis, in human serum or plasma.

A team of investigators working at the Institut Pasteur de Madagascar (Antananarivo, Madagascar) tested a collection of reference serum samples which included 14 defined cysticercosis serum samples, 100 serum samples positive for T. solium antibodies, 99 negative samples, and 60 sera from patients with other parasitic infections. All sera were tested both by enzyme-linked immunosorbent assays (ELISA) and by an immunoblot method, the enzyme-linked immunoelectrotransfer blot (EITB). The ELISA tests compared in the study were the DRG T. solium IgG (Cysticercosis); RIDASCREEN T. solium IgG; NOVATECH NovaLisa T. solium IgG; CYPRESS Cysticercosis Ab (T. solium); and the IVD Cysticercosis (T. solium) Microwell Serum ELISA.

The Ridascreen test (R-Biopharm; Darmstadt, Germany) had the best positive EITB concordance rate of between 85.1%-91.2%, followed by the Cypress test (Cypress; Langdorp, Belgium) with results between 71.0%-77.2%. The NovaLisa test (NovaTec Immunodiagnostica; Dietzenback, Germany) showed the optimal negative concordance rate of between 93.7%-95.6% when compared with the EITB, as did the DRG Diagnostics test (DRG International; Mountainside, NJ, USA) at 93.7%. All tests had a sensitivity under 72% and if equivocal specimens are considered negative, four of the tests, DRG, NOVALISA, CYPRESS, and IVD (IVD Research; Carlsbad, CA, USA) display a sensitivity under 50%.

Cross-reactivity with non-neurocysticercosis sera was observed for all tests for all the sera positive for Echinococcus granulosis antibodies. E. multilocularis–positive sera gave false-positive reactions for most of the tests. Except for these common cross-reactions, very few other cross-reactions were encountered with the DRG Diagnostics test and the NovaLisa test. The authors concluded that for the commercial assays they evaluated, the most appropriate ELISA test for screening might be the Ridascreen assay. However, antibody detection seems to be not appropriate for the diagnosis of neurocysticercosis because of its overall lack of sensitivity. The study was published in the January issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

Institut Pasteur de Madagascar
R-Biopharm
Cypress





Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: A diagnostic test can distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone (Photo courtesy of University of Turku)

Novel Diagnostic Tool to Revolutionize Treatment Guidance of Head and Neck Cancer

Head and neck squamous cell carcinoma (HNSCC) is a solid tumor type commonly treated with surgery. However, there has been no clinically available method to determine which patients can be cured with surgery... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.